Could a lower dose of blood cancer drugs be just as effective?
NCT ID NCT07474961
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial is for adults with multiple myeloma or Waldenstrom macroglobulinaemia. It tests whether giving certain drugs less often can control the disease as well as the standard schedule. The goal is to find the best balance between effectiveness and quality of life. About 400 people will take part across multiple hospitals.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
teclistamab, talquetamab, elranatamab, linvoseltamab, ibrutinib, zanubrutinib
What this could lead to
If successful, this could show that less frequent dosing of these drugs controls blood cancers just as well, reducing side effects and treatment burden.
What could go wrong
This is a Phase 4 trial that hasn't started recruiting yet. It's testing dose changes, not a new cure, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aalborg University Hospital
Aalborg, 9000, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Aarhus University Hospital
Aarhus, 8200, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Copenhagen University Hospital - Rigshospitalet
Copenhagen, Greater Copenhagen Area, 2100, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Odense University Hospital
Odense, 5000, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Roskilde University Hospital
Roskilde, 4000, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••